Skip to content

Comparison Between Initial Routine PICC and General IV Access in Terminally Ill Cancer Patients

Comparison of Safety, Efficacy, and Patient-perceived Satisfaction Between Initial Routine Peripherally Inserted Central Catheters Insertion and General Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03299868
Enrollment
66
Registered
2017-10-03
Start date
2017-05-01
Completion date
2020-06-30
Last updated
2020-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravenous Access, Peripherally Inserted Central Catheter

Keywords

Peripherally inserted central catheter, Terminally ill cancer patients, Palliative care

Brief summary

To establish the IV access strategy for terminally ill cancer patients, using comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (optional PICC group).

Detailed description

Reliable intravenous (IV) access is an important issue in terminally ill cancer patients, however, they have limited or no peripheral venous access due to edema or long period of IV therapy. Thus, intravenous access has been provided by Central venous catheter (CVC). There are some options for applying CVC in cancer patients; subclavian venous catheter (SVC), chemo-port (CP), and the peripherally inserted central catheter (PICC). When considering the characteristics of terminally ill cancer patients, such as poor general condition and a limited period of survival, PICC could be a safe and effective method for intravenous access. There are two previous studies concerned about PICC study in terminally ill cancer patients. They showed that PICC might be overall safe and efficient in terminally ill cancer patients. However, these studies did not evaluate superiority of PICC insertion compared to no insertion and the appropriate time for PICC insertion due to limitation of their design, such as retrospective or single-arm observational study. Thus, strategies of PICC insertion for IV access in terminally ill cancer patients have not been determined until now. Considering the favorable results of PICC insertion in previous studies and limited survival time of terminally ill cancer patients, the investigator postulated that routine PICC insertion at the time of admission for terminal care would be effective for IV access. Thus, the investigator assumed that initially routine PICC insertion would be non-inferior in maintenance success rate / and complication rate compared to general IV access. In addition, it would be superior in patient-perceived satisfaction. The inveistigator will undertake a randomized phase II study to confirm the hypothesis.

Interventions

comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)

Sponsors

Pusan National University Yangsan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective, Single institution, Open-label, Randomized, Phase 2

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Cancer patients with histologically or cytologically confirmed malignancy and fulfilled all of the following conditions 2. Patients with expected survival time of 3 months or less due to a progressive disease without additional anticancer treatment. (However, palliative radiation treatment for symptom control is allowed.) 3. Patients who need the IV access route continuously for hydration or medication. 4. Age18 or older 5. Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed about all pertinent aspects of the trial prior to enrollment

Exclusion criteria

1. Patients who showed severe coagulopathy such as thrombocytopenia (Platelet count ≤ 20,000/mm2) or international normalized ratio (INR) prolongation (≥2.0 ) in spite of treatment 2. Patients who have an evidence of current sepsis (bacteremia or fungemia) 1. 'current' means bacteremia/fungemia without eradication on follow-up peripheral blood culture 2. patients with persistent fever (bacteremia or fungemia cannot be ruled out) 3. Patients who is impracticable to PICC insertion due to uncontrolled behavioral disorders

Design outcomes

Primary

MeasureTime frameDescription
IV access maintenance success rateFrom date of enrollment until death or discharge/transfer, assess up to 2 yearsrate of successful PICC maintenance until death or discharge/transfer

Secondary

MeasureTime frameDescription
PICC premature removal rateFrom date of enrollment until date of PICC removal, assess up to 2 yearsrate of premature removal such as self-removal or CRBSI before death or discharge
PICC life spanFrom date of enrollment until death or discharge/transfer, assess up to 2 yearsmedian survival of PICC
PICC related complication rateFrom date of enrollment until death or discharge/transfer, assess up to 2 yearsrate of any complication which is related with PICC
patient perceived comfort and convenience assessed by a newly developed question in this study3th to 7th day after enrollmentpatient perceived comfort and convenience (How do participants feel comfort and convenience about the IV access? at 3th - 7th days after enrollment
colonization of microbiology in PICCat the time of PICC removal, assess up to 2 yearsInvestigator evaluate the colonization of PICC using tip culture at the time of removal
patient perceived procedure-related distress5th day after procedureprocedure-related distress during insertion of PICC

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026